U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H12ClN3O2.ClH
Molecular Weight 326.178
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-863233 HYDROCHLORIDE

SMILES

Cl.[H][C@]1(CCCN1)C2=NC3=C(OC4=C3C=C(Cl)C=C4)C(=O)N2

InChI

InChIKey=UNDKJUKLBNARIZ-FVGYRXGTSA-N
InChI=1S/C14H12ClN3O2.ClH/c15-7-3-4-10-8(6-7)11-12(20-10)14(19)18-13(17-11)9-2-1-5-16-9;/h3-4,6,9,16H,1-2,5H2,(H,17,18,19);1H/t9-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H12ClN3O2
Molecular Weight 289.717
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20647475

BMS-863233, also known as XL413, is a potent and selective cell division cycle 7 (CDC7) kinase inhibitor with potential antineoplastic activity. BMS-863233 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induction of tumor cell apoptosis, and the inhibition of tumor cell proliferation in CDC7-overexpressing tumor cells. CDC7, a serine-threonine kinase overexpressed in a variety of tumor cell types, plays an essential role in the initiation of DNA replication by activating origins of replication.

Originator

Curator's Comment: # Exelixis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
215.0 nM [IC50]
42.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BMS-63233

Approved Use

Unknown
Primary
BMS-63233

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of XL413, a potent and selective CDC7 inhibitor.
2012 Jun 1
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
Prolonged treatment with BMS-863233 (XL413) during 3 days inhibited the cell proliferation (IC50 = 2685 nM), decreased cell viability (IC50 = 2142 nM) and elicited the caspase 3/7 activity (EC50 = 2288 nM) in human colorectal adenocarcinoma Colo-205 cells.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:42:11 GMT 2023
Edited
by admin
on Fri Dec 15 17:42:11 GMT 2023
Record UNII
JG305JRH1Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-863233 HYDROCHLORIDE
Common Name English
BENZOFURO(3,2-D)PYRIMIDIN-4(3H)-ONE, 8-CHLORO-2-((2S)-2-PYRROLIDINYL)-, MONOHYDROCHLORIDE
Common Name English
Code System Code Type Description
PUBCHEM
135564631
Created by admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
PRIMARY
DRUG BANK
DBSALT002181
Created by admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
PRIMARY
CAS
1169562-71-3
Created by admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
PRIMARY
FDA UNII
JG305JRH1Z
Created by admin on Fri Dec 15 17:42:11 GMT 2023 , Edited by admin on Fri Dec 15 17:42:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY